TradeOrgs
  • Stocks
  • Screener
  • Backtest
  • Watchlist
  • Signals
  • Portfolio
  • Insights
  • Connect
Sign in
RELIANCE₹1,304.00▼ 0.70%TCS₹2,093.50▼ 6.61%HDFCBANK₹801.05▲ 6.29%ICICIBANK₹1,411.40▲ 13.64%INFY₹1,047.20▼ 14.35%HINDUNILVR₹2,201.20▲ 5.29%ITC₹289.95▲ 4.68%SBIN₹1,040.00▲ 7.17%BHARTIARTL₹1,910.40▲ 4.73%KOTAKBANK₹396.75▲ 4.13%LT₹4,026.60▲ 1.86%AXISBANK₹1,342.10▲ 6.92%ASIANPAINT₹2,737.80▲ 2.83%MARUTI₹14,366.00▲ 10.13%AAPL$308.63▼ 2.08%MSFT$390.49▼ 11.52%GOOGL$359.91▼ 0.54%AMZN$242.67▼ 5.40%NVDA$194.83▼ 12.56%META$582.90▼ 2.46%TSLA$393.45▼ 7.15%BRK-B$507.78▲ 7.69%JPM$334.47▲ 11.13%V$362.13▲ 14.12%
RELIANCE₹1,304.00▼ 0.70%TCS₹2,093.50▼ 6.61%HDFCBANK₹801.05▲ 6.29%ICICIBANK₹1,411.40▲ 13.64%INFY₹1,047.20▼ 14.35%HINDUNILVR₹2,201.20▲ 5.29%ITC₹289.95▲ 4.68%SBIN₹1,040.00▲ 7.17%BHARTIARTL₹1,910.40▲ 4.73%KOTAKBANK₹396.75▲ 4.13%LT₹4,026.60▲ 1.86%AXISBANK₹1,342.10▲ 6.92%ASIANPAINT₹2,737.80▲ 2.83%MARUTI₹14,366.00▲ 10.13%AAPL$308.63▼ 2.08%MSFT$390.49▼ 11.52%GOOGL$359.91▼ 0.54%AMZN$242.67▼ 5.40%NVDA$194.83▼ 12.56%META$582.90▼ 2.46%TSLA$393.45▼ 7.15%BRK-B$507.78▲ 7.69%JPM$334.47▲ 11.13%V$362.13▲ 14.12%

TradeOrgs shows market information and analyzes your own trading history. It does not place trades and is not investment advice.

Prices and listings are for information only. We are read-only against your broker account.

Technical signals (RSI, MACD, etc.) are educational readouts of public indicators — not recommendations.

Privacy Policy·© 2026 TradeOrgs

← All stocks

🇮🇳AKUMS

AKUMS

NSE
₹626.80
▲ ₹86.35 (+16.0%)
Live· just now
delayed feed · not for order timing

Price history · 20-day (cyan) / 50-day (purple) avg

as of 03 Jul 2026
H ₹645.00L ₹409.30+46.7%
₹645₹597.86₹550.72₹503.58₹456.44₹409.3₹626.8
RSI (14)
Intraday · 15-minSell-20RSI 46DowntrendMACD Bullishfor day-trading context — not advice

Technical signal

Strong buy+60
RSI (14)65
oversold 30overbought 70
Trend
Uptrend
MACD
Bullish
Bollinger
Within bands
vs 20-day
above
vs 50-day
above
vs 200-day
above
Support
₹542.85
Resistance
₹645.00
  • Price is above its 50-day average (medium-term uptrend).
  • Price is above its 200-day average (long-term uptrend).

Signal backtest · 2025-09-29 → 2026-07-03

Strategy return
+25.5%
Buy & hold
+41.3%
Trades
7
Win rate
14%

₹1,00,000.00 invested would be worth ₹1,25,491.50 (+25.5%) · Full backtester →

Hypothetical: go long when the signal turns Buy, exit when it turns Sell. Past indicator behavior is not a prediction — educational only, not advice.

About AKUMS DRUGS AND PHARMA L· Drug Manufacturers - Specialty & Generic

source: yahoo

Akums Drugs and Pharmaceuticals Limited manufactures and sells pharmaceutical products and active pharmaceutical ingredients India and internationally. The company provides drugs, ayurvedic, nutraceuticals, food and dietary supplements, derma and cosmetics, healthcare and hospital products, over-the-counter (OTC) products, active pharmaceutical ingredients, excipients, and compounds. It also offers branded formulations on various dosage forms, including tablets, hard and soft gelatin capsules, liquid orals, sachets, vials, ampoules, form-fill-seal products, topical preparations, eye drops, dry powder injections, and gummies for therapeutic areas, such as antiinfectives, pain management, gastroenterology, orthopaedics, cardio-diabetic care, critical care, respiratory, and gynaecology. In addition, the company operates as pharmaceutical contract development and manufacturing company. Akums Drugs and Pharmaceuticals Limited was incorporated in 2004 and is based in Delhi, India.

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
7,337
Headquarters
Delhi, India
www.akums.in ↗

Fundamentals

source: yahoo
Market cap
₹9.6KCr
P/E
37.6
P/B
2.9
EPS
₹16.67
Div yield
0.2%
Profit margin
5.9%
ROE
8.0%
Debt / Equity
0.06
Beta
—
52-week range
₹409.30 – ₹645.00
52-week low · ₹409.3092% of rangehigh · ₹645.00

Fundamental data is informational only — not investment advice.

Recent news

News sentiment:▲ Positive2↑ · 1↓ · 5–
  • Jim Cramer on Cardinal Health: “It’s Been a Real Stalwart, and I Don’t Think It’s Done”— Neutral
    Insider Monkey · 04 Jul 2026
  • Jim Cramer Says He Bets “The Gains in CVS Will Be Long-Lasting”▲ Positive
    Insider Monkey · 04 Jul 2026
  • Jim Cramer Says He Would Avoid Blue Owl and Prefers Blackstone— Neutral
    Insider Monkey · 04 Jul 2026
  • Jim Cramer on Palantir: “This Is the Fastest Grower of the Stocks I Follow, and It’s Been Crushed”

Educational technical indicators — not investment advice. TradeOrgs does not place trades.

— Neutral
Insider Monkey · 04 Jul 2026
  • EPR's CFO Sold Shares at a Premium — Here's the Bet Behind the Stock— Neutral
    Motley Fool · 04 Jul 2026
  • Scope Ratings assigns AA- long -term ratings to the Republic of Iceland with Stable Outlook— Neutral
    GlobeNewswire · 04 Jul 2026
  • Sentiment is a keyword-based read of the headline — a rough signal, not advice.